Post-COVID Arrhythmia Risk Model (Autonomic + ECG) Calculator

Clinical calculation support · Verify results before clinical use

Patient assessment

Enter clinical and ECG/HRV findings. This is a non-validated heuristic, not a clinical prediction score.

—Points
Interpret according to recording duration and method.
Confirm measurement, correction formula, heart rate and clinical context.
The source rule mentions ΔHR ≥30 bpm within 10 minutes standing; diagnosis requires clinical context.
For example, LV dysfunction, myocardial scar or significant valve disease.
Reset calculator

About this assessment

This tool combines autonomic, ECG, rhythm-monitoring and clinical features potentially relevant to symptoms after COVID-19. It reproduces the supplied point rules for transparency; it is not a validated prediction model and must not rule out arrhythmia or determine disposition by itself.

Interpretation limits

  • HRV depends on recording duration, signal quality, rhythm, age, medications and other factors. SDNN from 24-hour and short-term recordings are not interchangeable.
  • QTc thresholds vary by reference and setting. Confirm measurement and correction method, review medicines and correct electrolytes when indicated.
  • PVC burden is associated with PVC-induced cardiomyopathy in selected populations, but thresholds from ablation cohorts are not universal risk cutoffs.
  • Syncope, sustained arrhythmia, marked QT prolongation, hemodynamic instability, chest pain or worsening dyspnea require clinical assessment regardless of score.

Supplied point rules (not validated)

FeatureRule in source codePoints
SDNN<50 / 50–99 ms3 / 1
RMSSD<20 / 20–29 ms2 / 1
QTc, male/female450/460 borderline; 470/480 prolonged; ≥500 marked1 / 2 / 4
PVC burden1–9.9 / 10–24.9 / ≥25%1 / 3 / 4
Resting HR90–109 / ≥110 bpm1 / 2
Clinical featuresPOTS, syncope, structural disease; infection 1–6 weeks prior2 each; 1 for timing

References

Gopinathannair R, et al. Cardiac arrhythmias and autonomic dysfunction associated with COVID-19: A scientific statement from the American Heart Association. Circulation. 2024.doi:10.1161/CIR.0000000000001290
Task Force of the ESC and NASPE. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. 1996.doi:10.1161/01.CIR.93.5.1043
Khatib R, et al. Managing drug-induced QT prolongation in clinical practice. Postgraduate Medical Journal. 2021.doi:10.1136/postgradmedj-2020-138661 · PMID 33122341
Baman TS, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010.doi:10.1016/j.hrthm.2010.03.036 · PMID 20348027

These sources support context only; they do not validate the composite score or its weights.

Clinical disclaimer: Educational decision support only. This custom score has no established external validation, calibration, sensitivity, specificity or outcome-linked risk categories. Clinical judgement and applicable guidelines take precedence. Do not delay urgent assessment because of a low score.